Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | STAT5B | P51692 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395909 | 0.89 | HTR2C (0.44) | HTR2CSLC6A4 | |
| SCHEMBL4406792 | 0.86 | JAK2 (0.41) | — | |
| SCHEMBL25048390 | 0.78 | BRD4 (0.47) | KMONAAAHTR1AL3MBTL1 | |
| SCHEMBL4397958 | 0.78 | ACACB (0.42) | — | |
| SCHEMBL4404678 | 0.78 | GRM5 (0.49) | — | |
| SCHEMBL8635430 | 0.77 | AKT1 (0.44) | HDAC2GRM2HTR2CSLC6A4L3MBTL1 | |
| SCHEMBL4399211 | 0.77 | ACACB (0.46) | — | |
| SCHEMBL4398493 | 0.77 | EPHX2 (0.43) | DRD2 | |
| SCHEMBL4403349 | 0.76 | LMNA (0.44) | — | |
| SCHEMBL7145500 | 0.76 | SLC2A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2021-01-12 | — | — | US | disclosed |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | VERNALIS (R&D) LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| EP-2832726-B1 | (2-HETEROARYLAMINO)SUCCINIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2832726-B1 | (2-HETEROARYLAMINO)SUCCINIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9206168-B2 | (2-heteroarylamino) succinic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206168-B2 | (2-heteroarylamino) succinic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206168-B2 | (2-heteroarylamino) succinic acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2832726-A1 | (2-HETEROARYLAMINO)SUCCINIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832726-A1 | (2-HETEROARYLAMINO)SUCCINIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-04 | — | — | EP | disclosed |
| CN-104334528-A | (2-heteroarylamino) succinic acid derivatives | DAIICHI SANKYO CO LTD | 2015-02-04 | — | — | CN | disclosed |
| US-20150011574-A1 | (2-HETEROARYLAMINO) SUCCINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | VERNALIS (R&D) LIMITED (GB) | 2015-01-08 | — | — | US | disclosed |
| US-20150011574-A1 | (2-HETEROARYLAMINO) SUCCINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011574-A1 | (2-HETEROARYLAMINO) SUCCINIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011574-A1 | (2-HETEROARYLAMINO) SUCCINIC ACID DERIVATIVES | EPOR, EGLN2, EGLN3 | CETP 3878/4885KMO 1170/4885NAAA 2051/4885 |
| US-10000481-B2 | 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | CETP 4866/4885KMO 867/4885NAAA 3971/4885 |
| US-20180362526-A1 | 1H-PYRROLO [2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | CETP 4866/4885KMO 867/4885NAAA 3971/4885 |
| US-10889582-B2 | 1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors | MAP4K2, MAP3K1, MAP3K19 | CETP 4866/4885KMO 867/4885NAAA 3971/4885 |
| US-20150011533-A1 | 1H-PYRROLO[2,3-B] PYRIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | MAP4K2, MAP3K1, MAP3K19 | CETP 4866/4885KMO 867/4885NAAA 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.